DISCO Pharmaceuticals uses groundbreaking proteomics technology to map the cancer cell surfaceome. has pioneered the initial surfaceome mapping for Small Cell Lung Cncer (SCLC) and Colorectal Cancer (CRC). The company is currently advancing multiple ADC candidates toward studies that will enable submission for Investigational New Drug (IND) status.
Included in the AvH investment portfolio since 2025.
10.89 %
Press releases - Growth capital
View AllRelated participations
Growth Capital
Biotalys
Biotalys has developed a unique and versatile technological platform for the development of new protein-based biological crop protection products that provide a safe, sustainable and efficient protection for seeds, crops and food.
Growth Capital
Confo Therapeutics
Confo's mission is to develop novel GPCR modulators for patients with severe and underserved diseases, with a current emphasis on rare diseases, peripheral pain and obesity.
Growth Capital
Vico Therapeutics
Vico Therapeutics is a Dutch biotech company developing novel Antisense-Oligonucleotide (ASO) therapies for rare diseases.